Sugi Predict

Sugi Predict / Compounds / SCHEMBL1617865

SCHEMBL1617865

SCHEMBL1617865

CN(C)CCN(C)Cc1ccc(-c2ccc(S(=O)(=O)N3CCN(c4ncc(C(=O)NO)cn4)CC3)cc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 16/20 0.55
▸ HDAC3 O15379 15/20 0.55
▸ HDAC2 Q92769 15/20 0.55
▸ HDAC6 Q9UBN7 15/20 0.55
▸ HDAC4 P56524 13/20 0.55
▸ HDAC7 Q8WUI4 13/20 0.55
▸ HDAC10 Q969S8 13/20 0.55
▸ HDAC11 Q96DB2 13/20 0.55
▸ HDAC8 Q9BY41 13/20 0.55
▸ HDAC9 Q9UKV0 13/20 0.55
▸ HDAC5 Q9UQL6 13/20 0.55
▸ LMNA P02545 1/20 0.41
▸ NAMPT P43490 1/20 0.41
▸ PDE5A O76074 1/20 0.40
▸ NCOR2 Q9Y618 1/20 0.40
▸ KDM1A O60341 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1617860 0.92 HDAC1 (0.59) HDAC1HDAC3HDAC2HDAC6HDAC4
SCHEMBL1618273 0.87 HDAC1 (0.55) HDAC1HDAC3HDAC2HDAC6HDAC4
SCHEMBL1618872 0.86 HDAC1 (0.49) HDAC1HDAC3HDAC2HDAC6HDAC4
SCHEMBL1618724 0.85 HDAC1 (0.56) HDAC1HDAC3HDAC2HDAC6HDAC4
SCHEMBL1618203 0.84 HDAC3 (0.57) HDAC1HDAC3HDAC2HDAC6HDAC4
SCHEMBL1618699 0.84 HDAC1 (0.63) HDAC1HDAC3HDAC2HDAC6HDAC4
SCHEMBL1662073 0.83 HDAC3 (0.57) HDAC1HDAC3HDAC2HDAC6HDAC4
SCHEMBL1617703 0.83 HDAC3 (0.58) HDAC1HDAC3HDAC2HDAC6HDAC4
SCHEMBL1662954 0.82 HDAC6 (0.41) HDAC1HDAC3HDAC2HDAC6HDAC4
SCHEMBL1619073 0.82 HDAC3 (0.66) HDAC1HDAC3HDAC2HDAC6HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8865720-B2 Sulfonyl-derivatives as novel inhibitors of histone deacetylase JANSSEN PHARMACEUTICA NV (BE) 2014-10-21 — — US disclosed
US-8865720-B2 Sulfonyl-derivatives as novel inhibitors of histone deacetylase JANSSEN PHARMACEUTICA NV (BE) 2014-10-21 — — US disclosed
US-20140038979-A1 SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE JANSSEN PHARMACEUTICA NV (BE) 2014-02-06 — — US disclosed
US-20140038979-A1 SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE JANSSEN PHARMACEUTICA NV (BE) 2014-02-06 — — US disclosed
US-8557825-B2 Sulfonyl-derivatives as novel inhibitors of histone deacetylase JANSSEN PHARMACEUTICA N.V. (BE) 2013-10-15 — — US disclosed
US-8557825-B2 Sulfonyl-derivatives as novel inhibitors of histone deacetylase JANSSEN PHARMACEUTICA N.V. (BE) 2013-10-15 — — US disclosed
US-20120088754-A1 SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE EMELEN KRISTOF VAN (BE) 2012-04-12 — — US disclosed
US-8097611-B2 Sulfonyl-derivatives as novel or histone deacetylase JANSSEN PHARMACEUTICA, N.V. (BE) 2012-01-17 — — US disclosed
US-8097611-B2 Sulfonyl-derivatives as novel or histone deacetylase JANSSEN PHARMACEUTICA, N.V. (BE) 2012-01-17 — — US disclosed
US-20100240639-A1 Sulfonyl-Derivatives as Novel or Histone Deacetylase VAN EMELEN KRISTOF 2010-09-23 — — US disclosed
US-20100240639-A1 Sulfonyl-Derivatives as Novel or Histone Deacetylase VAN EMELEN KRISTOF 2010-09-23 — — US disclosed
US-7709487-B2 anticancer agents; can be combined with other HDAC inhibitors JANSSEN PHARMACEUTICA NV (BE) 2010-05-04 — — US disclosed
US-7704998-B2 anticancer agents; catalytic hydrogenation JANSSEN PHARMACEUTICA N.V. (BE) 2010-04-27 — — US disclosed
US-20090270419-A1 COMBINATIONS OF CLASS-I SPECIFIC HISTONE DEACETYLASE INHIBITORS WITH PROTEASOME INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2009-10-29 — — US disclosed
US-20080108601-A1 anticancer agents; catalytic hydrogenation VAN EMELEN KRISTOF 2008-05-08 — — US disclosed
WO-2008031820-A2 COMBINATIONS OF CLASS-I SPECIFIC HISTONE DEACETYLASE INHIBITORS WITH PROTEASOME INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2008-03-20 — — WO disclosed
US-20070142393-A1 SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE EMELEN KRISTOF V 2007-06-21 — — US disclosed
US-7205304-B2 medicine to inhibit proliferative conditions, such as cancer and psoriasis JANSSEN PHARMACEUTICA N.V. (BE) 2007-04-17 — — US disclosed
US-7205304-B2 medicine to inhibit proliferative conditions, such as cancer and psoriasis JANSSEN PHARMACEUTICA N.V. (BE) 2007-04-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088754-A1 SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE HDAC3, HDAC1, HDAC11 HDAC1 2/4885HDAC3 1/4885HDAC2 5/4885
US-20140038979-A1 SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE HDAC3, HDAC1, HDAC11 HDAC1 2/4885HDAC3 1/4885HDAC2 5/4885
US-20090270419-A1 COMBINATIONS OF CLASS-I SPECIFIC HISTONE DEACETYLASE INHIBITORS WITH PROTEASOME INHIBITORS HDAC1, PSME1, PSMB1 HDAC1 1/4885HDAC3 33/4885HDAC2 44/4885
US-20100240639-A1 Sulfonyl-Derivatives as Novel or Histone Deacetylase HDAC3, HDAC1, HDAC11 HDAC1 2/4885HDAC3 1/4885HDAC2 4/4885
US-20070142393-A1 SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE HDAC3, HDAC1, HDAC11 HDAC1 2/4885HDAC3 1/4885HDAC2 5/4885
US-20080108601-A1 anticancer agents; catalytic hydrogenation HDAC1, HDAC11, HDAC3 HDAC1 1/4885HDAC3 3/4885HDAC2 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.